SAN DIEGO--(BUSINESS WIRE)--Sept. 6, 2006--Inovio Biomedical Corporation (AMEX:INO) announced today the grant of an additional patent, from the European Patent Office (EPO), further expanding its electroporation technology platform. This patent (EP1023107) enhances the company’s intellectual property portfolio for electroporation in Europe with claims related to the delivery of DNA-based therapeutics into muscle, the preferred tissue for extended production of antigens and other bioactive agents integral to gene therapy and DNA vaccination. The patent includes claims covering the most desirable pulsing and agent delivery conditions using electroporation.
